A forum for researchers, students and applicants in the field of cyclodextrin technology
Axsome Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug SBECD-enabled remdesivir to accelerate its emergency use for multiple
University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
Gilead Sciences’ SBECD-enabled remdesivir (GS-5734) was highlighted in the New England Journal of Medicine last week for treating the first
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,
